Evolus Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.21
- Today's High:
- $9.63
- Open Price:
- $9.51
- 52W Low:
- $6.51
- 52W High:
- $14.29
- Prev. Close:
- $9.55
- Volume:
- 240822
Company Statistics
- Market Cap.:
- $499.78 million
- Book Value:
- 0.122
- Revenue TTM:
- $156.43 million
- Operating Margin TTM:
- -34.42%
- Gross Profit TTM:
- $92.73 million
- Profit Margin:
- -45.84%
- Return on Assets TTM:
- -17.67%
- Return on Equity TTM:
- -193.28%
Company Profile
Evolus Inc had its IPO on 2018-02-08 under the ticker symbol EOLS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Evolus Inc has a staff strength of 224 employees.
Stock update
Shares of Evolus Inc opened at $9.51 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.21 - $9.63, and closed at $9.23.
This is a -3.35% slip from the previous day's closing price.
A total volume of 240,822 shares were traded at the close of the day’s session.
In the last one week, shares of Evolus Inc have slipped by -6.86%.
Evolus Inc's Key Ratios
Evolus Inc has a market cap of $499.78 million, indicating a price to book ratio of 14.6487 and a price to sales ratio of 2.9729.
In the last 12-months Evolus Inc’s revenue was $156.43 million with a gross profit of $92.73 million and an EBITDA of $-49833000. The EBITDA ratio measures Evolus Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Evolus Inc’s operating margin was -34.42% while its return on assets stood at -17.67% with a return of equity of -193.28%.
In Q1, Evolus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 23%.
Evolus Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evolus Inc’s profitability.
Evolus Inc stock is trading at a EV to sales ratio of 3.1296 and a EV to EBITDA ratio of -6.3881. Its price to sales ratio in the trailing 12-months stood at 2.9729.
Evolus Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $160.24 million
- Total Liabilities
- $40.68 million
- Operating Cash Flow
- $-511000.00
- Capital Expenditure
- $511000
- Dividend Payout Ratio
- 0%
Evolus Inc ended 2024 with $160.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $160.24 million while shareholder equity stood at $6.95 million.
Evolus Inc ended 2024 with $0 in deferred long-term liabilities, $40.68 million in other current liabilities, 1000.00 in common stock, $-512085000.00 in retained earnings and $21.21 million in goodwill. Its cash balance stood at $31.46 million and cash and short-term investments were $31.46 million. The company’s total short-term debt was $1,334,000 while long-term debt stood at $72.05 million.
Evolus Inc’s total current assets stands at $84.09 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $23.46 million compared to accounts payable of $10.19 million and inventory worth $23.42 million.
In 2024, Evolus Inc's operating cash flow was $-511000.00 while its capital expenditure stood at $511000.
Comparatively, Evolus Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $9.23
- 52-Week High
- $14.29
- 52-Week Low
- $6.51
- Analyst Target Price
- $17.67
Evolus Inc stock is currently trading at $9.23 per share. It touched a 52-week high of $14.29 and a 52-week low of $14.29. Analysts tracking the stock have a 12-month average target price of $17.67.
Its 50-day moving average was $8.91 and 200-day moving average was $8.64 The short ratio stood at 4.75 indicating a short percent outstanding of 0%.
Around 2405% of the company’s stock are held by insiders while 5811.9% are held by institutions.
Frequently Asked Questions About Evolus Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.